5-氨基-2-巯基噻唑 | 6294-51-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氨基-2-巯基噻唑
• 英文名称: 5-amino-1,3-thiazole-2-thiol
• 英文别名: 5-aminothiazole-2-mercaptan；5-amino-2-mercaptothiazole；5-aminothiazole-2-thiol；5-amino-3H-1,3-thiazole-2-thione
• CAS: 6294-51-5
• 化学式: C₃H₄N₂S₂
• 分子量: 132.21
• InChiKey: RYFCSYHXNOKHCK-UHFFFAOYSA-N

物化性质

• 熔点：
  220-230 °C
• 沸点：
  239℃
• 密度：
  1.58
• 闪点：
  98℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  乙酰氯 、 5-氨基-2-巯基噻唑 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 以16%的产率得到[[5-(acetylamino)-2-thiazolyl]thio]acetic acid, methyl ester
  参考文献：
  名称：

  Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2:  Synthesis, X-ray Crystallographic Analysis, and Biological Activities

  摘要：

  High throughput screening identified 2-acetamido-thiazolylthio acetic ester 1 as an inhibitor of cyclin-dependent kinase 2 (CDK2). Because this compound is inactive in cells and unstable in plasma, we have stabilized it to metabolic hydrolysis by replacing the ester moiety with a 5-ethyl-substituted oxazole as in compound 14. Combinatorial and parallel synthesis provided a rapid analysis of the structure-activity relationship (SAR) for these inhibitors of CDK2, and over 100 analogues with IC50 values in the 1-10 nM range were rapidly prepared. The X-ray crystallographic data of the inhibitors bound to the active site of CDK2 protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues displayed potent and broad spectrum antiproliferative activity across a panel of tumor cell lines in vitro. In addition, A2780 ovarian carcinoma cells undergo rapid apoptosis following exposure to CDK2 inhibitors of this class. Mechanism of action studies have confirmed that the phosphorylation of CDK2 substrates such as RB, histone H1, and DNA polymerase alpha (p70 subunit) is reduced in the presence of compound 14. Further optimization led to compounds such as water soluble 45, which possesses a favorable pharmacokinetic profile in mice and demonstrates significant antitumor activity in vivo in several murine and human models, including an engineered murine mammary tumor that overexpresses cyclin E, the coactivator of CDK2.

  DOI：

  10.1021/jm0201520
• 作为产物：
  描述：

  二硫化碳 、 氨基乙腈 以 乙酸乙酯 为溶剂， 反应 1.0h， 生成 5-氨基-2-巯基噻唑
  参考文献：
  名称：

  纳西多酸的噻唑并吡啶类似物。1。噻唑并[5,4- b ]吡啶

  摘要：

  合成了一系列2-取代的-7-烷基-4,7-二氢-4-氧噻唑并[5,4 - b ]吡啶-5-羧酸。体外测试抗菌活性。所制备的新化合物均未在体外显示出对所测试菌株的任何抗菌活性。

  DOI：

  10.1002/jhet.5570210226

文献信息

• [EN] SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] COMPOSÉS DE SULFONYLE QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE LA GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2013123444A1

  公开（公告）日：2013-08-22

  The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的磺酰基化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  申请人：Savira Pharmaceuticals GmbH

  公开号：US20130317021A1

  公开（公告）日：2013-11-28

  The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及具有通式（C）的化合物，可选地以药学上可接受的盐、溶剂合物、多型体、共药、共晶、前药、互变异构体、外消旋体、对映体或二对映体或其混合物的形式存在，这些化合物在治疗、改善或预防病毒性疾病方面是有用的。此外，还披露了特定的联合疗法。
• 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  申请人：Savira Pharmaceuticals GmbH

  公开号：US20130317022A1

  公开（公告）日：2013-11-28

  The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及具有通式（A）的化合物，可选地以药学上可接受的盐、溶剂合物、多型体、共药、共晶、前药、互变异构体、外消旋体、对映体或二对映体或其混合物的形式存在，这些化合物在治疗、缓解或预防病毒性疾病方面是有用的。此外，还披露了特定的联合疗法。
• Cephem compounds and pharmaceutical use thereof
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06150351A1

  公开（公告）日：2000-11-21

  This invention relates to new cephem compound represented by the following general formula (I): ##STR1## wherein each symbol is as defined in the specification or a salt thereof, which has antimicrobial activity against Helicobacter pylori, and are useful as anti-Helicobacter pylori agents, anti-gastritis agents, anti-ulcer agents and anti-cancer agents.

  本发明涉及一种新的头孢菌素化合物，其通式表示为以下通式(I)：##STR1## 其中每个符号如规范中所定义或其盐，具有抗幽门螺杆菌活性，并且可用作抗幽门螺杆菌剂、抗胃炎剂、抗溃疡剂和抗癌剂。
• 一种具有噻唑侧链的截短侧耳素衍生物及其制备方法和应用
  申请人：华南农业大学

  公开号：CN117304133A

  公开（公告）日：2023-12-29

  本发明属于药物化学领域，公开了一种具有噻唑侧链的截短侧耳素衍生物及其制备方法和应用。所述衍生物为式2所示结构的化合物或其药学上可接受的盐。本发明提供的截短侧耳素衍生物是未曾报道过的新类型化合物，水溶性好，特别适合作为新型抗菌药物用于防治人或动物细菌感染性疾病，尤其是耐药金黄色葡萄球菌引起的感染性疾病，本发明制得的具有噻唑侧链的截短侧耳素衍生物水溶性好。#imgabs0#